Theralase Technologies Inc.
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $0.17
- Today's High:
- $0.18
- Open Price:
- $0.18
- 52W Low:
- $0.16
- 52W High:
- $0.32
- Prev. Close:
- $0.17
- Volume:
- 106000
Company Statistics
- Market Cap.:
- $38.25 million
- Book Value:
- 0.009
- Revenue TTM:
- $1.01 million
- Operating Margin TTM:
- -478.99%
- Gross Profit TTM:
- $628174
- Profit Margin:
- 0%
- Return on Assets TTM:
- -82.43%
- Return on Equity TTM:
- -211.14%
Company Profile
Theralase Technologies Inc. had its IPO on under the ticker symbol TLTFF.
The company operates in the Healthcare sector and Medical Devices industry. Theralase Technologies Inc. has a staff strength of 0 employees.
Stock update
Shares of Theralase Technologies Inc. opened at $0.18 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $0.17 - $0.18, and closed at $0.17.
This is a 0% increase from the previous day's closing price.
A total volume of 106,000 shares were traded at the close of the day’s session.
In the last one week, shares of Theralase Technologies Inc. have increased by 0%.
Theralase Technologies Inc.'s Key Ratios
Theralase Technologies Inc. has a market cap of $38.25 million, indicating a price to book ratio of 20.0096 and a price to sales ratio of 52.9225.
In the last 12-months Theralase Technologies Inc.’s revenue was $1.01 million with a gross profit of $628174 and an EBITDA of $-4636936. The EBITDA ratio measures Theralase Technologies Inc.'s overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Theralase Technologies Inc.’s operating margin was -478.99% while its return on assets stood at -82.43% with a return of equity of -211.14%.
In Q1, Theralase Technologies Inc.’s quarterly earnings growth was a positive 0% while revenue growth was a negative 35.8%.
Theralase Technologies Inc.’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
- 0
Its diluted EPS in the last 12-months stands at $-0.02 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of 0. A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Theralase Technologies Inc.’s profitability.
Theralase Technologies Inc. stock is trading at a EV to sales ratio of 50.4147 and a EV to EBITDA ratio of -9.7426. Its price to sales ratio in the trailing 12-months stood at 52.9225.
Theralase Technologies Inc. stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $3.20 million
- Total Liabilities
- $986527.00
- Operating Cash Flow
- $0
- Capital Expenditure
- $11870
- Dividend Payout Ratio
- 0%
Theralase Technologies Inc. ended 2024 with $3.20 million in total assets and $0 in total liabilities. Its intangible assets were valued at $3.20 million while shareholder equity stood at $1.85 million.
Theralase Technologies Inc. ended 2024 with $0 in deferred long-term liabilities, $986527.00 in other current liabilities, in common stock, $-60078080.00 in retained earnings and $0 in goodwill. Its cash balance stood at $365877.00 and cash and short-term investments were $0. The company’s total short-term debt was $0 while long-term debt stood at $0.
Theralase Technologies Inc.’s total current assets stands at $1.52 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $24866.00 compared to accounts payable of $505546.00 and inventory worth $572557.00.
In 2024, Theralase Technologies Inc.'s operating cash flow was $0 while its capital expenditure stood at $11870.
Comparatively, Theralase Technologies Inc. paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $0.17
- 52-Week High
- $0.32
- 52-Week Low
- $0.16
- Analyst Target Price
- $
Theralase Technologies Inc. stock is currently trading at $0.17 per share. It touched a 52-week high of $0.32 and a 52-week low of $0.32. Analysts tracking the stock have a 12-month average target price of $.
Its 50-day moving average was $0.2 and 200-day moving average was $0.22 The short ratio stood at 0 indicating a short percent outstanding of 0%.
Around 734% of the company’s stock are held by insiders while 0.2% are held by institutions.
Frequently Asked Questions About Theralase Technologies Inc.
Similar Industry Stocks (Medical Devices)
Most Active
Top Gainers
Top Losers
About
Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancers, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II for the treatment of Bacillus Calmette Guérin – Unresponsive Carcinoma In-Situ non-muscle invasive bladder cancer. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it provides controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine and therapy; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. It sells its products to healthcare practitioners. The company was incorporated in 1989 and is based in Toronto, Canada.